Carna Biosciences, Inc.
Stock Price Chart
2026/08/21 UpdatedPrice Trend
2026/08/21 UpdatedPrice & Trading Details
2026/08/21 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/08/01Major Holders
Updated 2026/08/01| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
SPDR (R) Idx Shares-SPDR (R) S&P (R) International Small Cap ETF
|
4.4K | 0.00% |
Financial Performance
2026/08/23 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥1,387M | ¥1,626M | ¥636M | ¥579M |
| Gross Profit | ¥1,215M | ¥1,451M | ¥466M | ¥388M |
| Operating Income | -¥1,270M | -¥1,117M | -¥2,076M | -¥2,075M |
| Pretax Income | -¥1,318M | -¥1,127M | -¥2,171M | -¥2,160M |
| Net Income | -¥1,350M | -¥1,153M | -¥2,179M | -¥2,171M |
| EPS | -¥99.10 | -¥68.62 | -¥121.64 | -¥113.62 |
| Operating Margin | -91.57% | -68.70% | -326.31% | -358.34% |
| Balance Sheet | ||||
| Total Assets | ¥4,266M | ¥4,350M | ¥2,772M | ¥1,230M |
| Total Equity | ¥3,642M | ¥3,878M | ¥2,475M | ¥309M |
| Total Liabilities | ¥625M | ¥472M | ¥297M | ¥920M |
| Cash | ¥3,379M | ¥2,889M | ¥2,108M | ¥517M |
| Interest-bearing Debt | ¥300M | ¥183M | ¥61M | ¥714M |
| Equity Ratio | 85.36% | 89.14% | 89.29% | 25.15% |
| D/E Ratio | 0.08 | 0.05 | 0.02 | 2.31 |
| Cash Flow | ||||
| Operating CF | -¥708M | -¥1,677M | -¥1,375M | -¥2,159M |
| Investing CF | -¥126M | -¥11M | -¥13M | -¥25M |
| Financing CF | ¥367M | ¥1,182M | ¥567M | ¥605M |
| Free CF | -¥834M | -¥1,689M | -¥1,388M | -¥2,169M |
| Efficiency | ||||
| ROE | -37.06% | -29.73% | -88.01% | -702.25% |
| ROA | -31.63% | -26.50% | -78.59% | -176.59% |
Latest IR Information
-
Notification on the Recognition of Non-Operating Expenses and Extraordinary Losses
Disclosure concerning the recognition of non-operating expenses and extraordinary losses. It is expected to detail items such as interest expense for the interim consolidated period and impairment, with continued explanations of financial impact.
Read more -
Karna Biotechnology, Inc. Second Quarter (Interim) Financial Summary〔Japanese GAAP〕(Consolidated)【2026-08-06】
Announces the results for the second quarter of the fiscal year ending December 2026. Net sales were 401 million yen (YoY +59.8%), operating loss was 954 million yen, and net loss attributable to owners of the parent for the interim...
Read more -
Executive Summary
Centering on the current state and future prospects of the pipeline, the positioning of the drug discovery support business and drug discovery business, and the status of key pipelines in clinical development; also describes market size, assumed share, and development...
Read more -
docirbrutinib (AS-1763) Development-Accelerating Stock Option Plan with Exercise Price Adjustment Clause – Monthly Exercise Status
Disclosure of the July 2026 monthly exercise status for the docirbrutinib (AS-1763) development-accelerating stock option. Shares issued: 40,000 shares; rights exercised: 400 (0.51% of issued shares). Unexercised rights at month-end: 7,570,300 shares. Exercise restriction ratio: 0.20%.
Read more -
FDA Orphan Drug Designation Acquired｜Karnaby BioScience July 2026
Karnaby BioScience has obtained orphan drug designation from the U.S. FDA for monzosertib (AS-0141), advancing clinical development. Expectations are high for accelerating development and securing market exclusivity in the future.
Read more
Latest News (5 items)
Company Information
About
Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops drug therapies to treat unmet medical needs in Japan. It offers kinase proteins and other protein products, including tyrosine, serine/threonine, lipid, inactive kinase, and pseudokinase; GST-tagged and Biotinylated; Protein Substrate; and Luciferase PPI Stable Cell Lines, such as GPCR and protein-protein interactions. The company also provides activity-based biochemical screening/profiling assay services comprising mobility shift assay/IMAP and AFP-Glo assay; and cell-based assay services which include NanoBRET TE intracellular kinase assay and split luciferase protein-protein interaction detection assay. In addition, it engages in developing monzosertib, an orally bioavailable small molecule inhibitor of cell division cycle 7 (CDC7) kinase that is in Phase 1 to treat various cancer cell lines, including solid and blood cancers; docirbrutinib, an orally bioavailable, non-covalent pan-inhibitor of wild type and mutant Bruton's tyrosine kinases for the treatment of chronic lymphocytic leukemia and other B-cell malignancies; and sofnobrutinib, a non-covalent Bruton's tyrosine kinases which is in clinical development to treat inflammatory and immune disorders. Carna Biosciences, Inc. was incorporated in 2003 and is headquartered in Kobe, Japan.
